277 related articles for article (PubMed ID: 28836749)
1. Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases.
Mathew AJ; Ganapati A; T SK; Goel R; P S; Danda D
J Assoc Physicians India; 2017 May; 65(5 Suppl):30-32. PubMed ID: 28836749
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis: A Real-life Experience.
Sharma B
J Assoc Physicians India; 2017 May; 65(5 Suppl):22-25. PubMed ID: 28836747
[TBL] [Abstract][Full Text] [Related]
3. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S; Chadwick L; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
Mengato D; Messori A
Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941
[No Abstract] [Full Text] [Related]
6. Switching from Other Biologics to ZRC3197 (Adalimumab Biosimilar) in Patients with Spondyloarthropathy: A Prospective Evaluation from Real-Life Clinical Practice.
Kapoor S
J Assoc Physicians India; 2017 May; 65(5 Suppl):26-29. PubMed ID: 28836748
[TBL] [Abstract][Full Text] [Related]
7. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
Nikolov NP; Shapiro MA
Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
[TBL] [Abstract][Full Text] [Related]
8. Review of Biosimilars of Adalimumab.
Kaushik VV
J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
[TBL] [Abstract][Full Text] [Related]
9. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars in pediatric rheumatology and their introduction into routine care.
Aragon Cuevas O; Hedrich CM
Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
Lu X; Hu R; Peng L; Liu M; Sun Z
Front Immunol; 2021; 12():638444. PubMed ID: 33889152
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
[TBL] [Abstract][Full Text] [Related]
14. FKB327: An Adalimumab Biosimilar.
Al-Salama ZT
BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort.
Popescu CC; Mogoșan CD; Enache L; Codreanu C
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557052
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
[TBL] [Abstract][Full Text] [Related]
17. Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
Schulze-Koops H
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv1-iv3. PubMed ID: 28903541
[No Abstract] [Full Text] [Related]
18. A Systematic Review Evaluating the Efficacy, Immunogenicity and Safety of the Biosimilar FKB327 in Treating Rheumatoid Arthritis.
Tanzeem F; Islam R
Mymensingh Med J; 2024 Jan; 33(1):313-319. PubMed ID: 38163811
[TBL] [Abstract][Full Text] [Related]
19. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
